Ozempic vs. Rybelsus
Ozempic and Rybelsus share the same active ingredient, semaglutide, but differ in formulation and administration. Ozempic is an injectable GLP-1 agonist, while Rybelsus is an oral alternative. Both target type 2 diabetes. Ozempic achieves superior HbA1c reductions and weight loss compared to Rybelsus. Both are used off-label for weight management. Common side effects, like nausea, overlap, though Rybelsus may carry a slightly higher risk of gastrointestinal discomfort. Ozempic costs $875/month, similar to Rybelsus’s $875/month. Neither drug faces current shortages.
Slows gastric emptying, reduces appetite, and enhances feelings of fullness, leading to lower calorie intake. It also stimulates insulin release and reduces glucagon secretion, improving blood sugar control.
Common Side Effects
Nausea, vomiting, diarrhea, constipation, and abdominal pain.
Serious Potential Side Effects
Pancreatitis, gallbladder issues, kidney problems, and increased heart rate, thyroid cancer, anaphylaxis (or serious allergic reactions)
Slows gastric emptying, reduces appetite, and enhances feelings of fullness, leading to lower calorie intake. It also stimulates insulin release and reduces glucagon secretion, improving blood sugar control.
Common Side Effects
Nausea, diarrhea, vomiting, and abdominal pain.
Serious Potential Side Effects
Pancreatitis, thyroid tumors (potential risk), gallbladder issues, kidney problems, and serious allergic reactions